Home Banner

For patients at risk of febrile neutropenia1

STIMUFEND®: Reimagining the pegfilgrastim experience

A continuum of support lets you focus on the battle against cancer

STIMUFEND has an established Q-Code: Q5127

See More Details

An FDA-approved biosimilar to Neulasta® (pegfilgrastim)1

established
Established biosimilarity
icon
See Biosimilarity Data
established
Fresenius Kabi: Outstanding heritage and commitment
icon Discover Our Manufacturing Reliability
established
Collaborative support through KabiCare
icon Learn About Patient Support Offerings

Request a representative

Receive information and news about STIMUFEND
Sign Up Now icon
Reference:
  1. STIMUFEND Prescribing Information. Fresenius Kabi USA, LLC; 2024 https://www.stimufendhcp.com/sites/default/files/documents/2024-02/stimufend_prescribinginfo_approved_2023.pdf